Serum levels of brain-derived neurotrophic factor in drug-naïve obsessive-compulsive patients: A case-control study

Giuseppe Maina, Gianluca Rosso, Roberta Zanardini, Filippo Bogetto, Massimo Gennarelli, Luisella Bocchio-Chiavetto

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Background: There is lack of data regarding BDNF serum levels in patients with obsessive-compulsive disorder (OCD). The aims of the present study were: 1) to assess the serum BDNF content in a sample of drug-naïve patients with OCD and 2) to assess whether putative alterations in peripheral BDNF may be associated to OCD severity and clinical characteristics. Methods: Twenty-four drug-naïve patients with a principal diagnosis of OCD were recruited. In parallel, a control group of 24 unrelated volunteers matched for gender and age was enrolled. Serum BDNF levels were measured by ELISA method. Results: The results showed that BDNF levels were decreased in OCD patients when compared to controls (36.90 ± 6.42 ng/ml versus 41.59 ± 7.82 ng/ml; p = 0.043). No correlations were evidenced between serum BDNF content and the severity of OCD symptoms measured as Y-BOCS scores or other clinical variables. Limitations: The choice of drug-naïve patients with obsessive-compulsive disorder had limited the size of the sample and excluded the recruitment of patients with a severe symptomatology. Conclusions: Our findings reveal for the first time in OCD patients a decrease in serum BDNF levels. These data corroborate the hypothesis of a dysfunction in the neurotrophin expression in the OCD pathogenetic mechanism and provide the rationale for further investigations directed to the identification of novel biomarkers and new therapeutic strategies for antiobsessional treatments.

Original languageEnglish
Pages (from-to)174-178
Number of pages5
JournalJournal of Affective Disorders
Volume122
Issue number1-2
DOIs
Publication statusPublished - Apr 2010

Fingerprint

Obsessive-Compulsive Disorder
Brain-Derived Neurotrophic Factor
Case-Control Studies
Serum
Pharmaceutical Preparations
Nerve Growth Factors
Sample Size
Patient Selection
Volunteers
Biomarkers
Enzyme-Linked Immunosorbent Assay
Control Groups
Therapeutics

Keywords

  • BDNF
  • Brain-derived neurotrophic factor
  • Drug-naïve
  • Obsessive-compulsive disorder
  • OCD
  • Serum

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Serum levels of brain-derived neurotrophic factor in drug-naïve obsessive-compulsive patients : A case-control study. / Maina, Giuseppe; Rosso, Gianluca; Zanardini, Roberta; Bogetto, Filippo; Gennarelli, Massimo; Bocchio-Chiavetto, Luisella.

In: Journal of Affective Disorders, Vol. 122, No. 1-2, 04.2010, p. 174-178.

Research output: Contribution to journalArticle

@article{f7c35467020e4e26a4755ddd2a95294c,
title = "Serum levels of brain-derived neurotrophic factor in drug-na{\"i}ve obsessive-compulsive patients: A case-control study",
abstract = "Background: There is lack of data regarding BDNF serum levels in patients with obsessive-compulsive disorder (OCD). The aims of the present study were: 1) to assess the serum BDNF content in a sample of drug-na{\"i}ve patients with OCD and 2) to assess whether putative alterations in peripheral BDNF may be associated to OCD severity and clinical characteristics. Methods: Twenty-four drug-na{\"i}ve patients with a principal diagnosis of OCD were recruited. In parallel, a control group of 24 unrelated volunteers matched for gender and age was enrolled. Serum BDNF levels were measured by ELISA method. Results: The results showed that BDNF levels were decreased in OCD patients when compared to controls (36.90 ± 6.42 ng/ml versus 41.59 ± 7.82 ng/ml; p = 0.043). No correlations were evidenced between serum BDNF content and the severity of OCD symptoms measured as Y-BOCS scores or other clinical variables. Limitations: The choice of drug-na{\"i}ve patients with obsessive-compulsive disorder had limited the size of the sample and excluded the recruitment of patients with a severe symptomatology. Conclusions: Our findings reveal for the first time in OCD patients a decrease in serum BDNF levels. These data corroborate the hypothesis of a dysfunction in the neurotrophin expression in the OCD pathogenetic mechanism and provide the rationale for further investigations directed to the identification of novel biomarkers and new therapeutic strategies for antiobsessional treatments.",
keywords = "BDNF, Brain-derived neurotrophic factor, Drug-na{\"i}ve, Obsessive-compulsive disorder, OCD, Serum",
author = "Giuseppe Maina and Gianluca Rosso and Roberta Zanardini and Filippo Bogetto and Massimo Gennarelli and Luisella Bocchio-Chiavetto",
year = "2010",
month = "4",
doi = "10.1016/j.jad.2009.07.009",
language = "English",
volume = "122",
pages = "174--178",
journal = "Journal of Affective Disorders",
issn = "0165-0327",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Serum levels of brain-derived neurotrophic factor in drug-naïve obsessive-compulsive patients

T2 - A case-control study

AU - Maina, Giuseppe

AU - Rosso, Gianluca

AU - Zanardini, Roberta

AU - Bogetto, Filippo

AU - Gennarelli, Massimo

AU - Bocchio-Chiavetto, Luisella

PY - 2010/4

Y1 - 2010/4

N2 - Background: There is lack of data regarding BDNF serum levels in patients with obsessive-compulsive disorder (OCD). The aims of the present study were: 1) to assess the serum BDNF content in a sample of drug-naïve patients with OCD and 2) to assess whether putative alterations in peripheral BDNF may be associated to OCD severity and clinical characteristics. Methods: Twenty-four drug-naïve patients with a principal diagnosis of OCD were recruited. In parallel, a control group of 24 unrelated volunteers matched for gender and age was enrolled. Serum BDNF levels were measured by ELISA method. Results: The results showed that BDNF levels were decreased in OCD patients when compared to controls (36.90 ± 6.42 ng/ml versus 41.59 ± 7.82 ng/ml; p = 0.043). No correlations were evidenced between serum BDNF content and the severity of OCD symptoms measured as Y-BOCS scores or other clinical variables. Limitations: The choice of drug-naïve patients with obsessive-compulsive disorder had limited the size of the sample and excluded the recruitment of patients with a severe symptomatology. Conclusions: Our findings reveal for the first time in OCD patients a decrease in serum BDNF levels. These data corroborate the hypothesis of a dysfunction in the neurotrophin expression in the OCD pathogenetic mechanism and provide the rationale for further investigations directed to the identification of novel biomarkers and new therapeutic strategies for antiobsessional treatments.

AB - Background: There is lack of data regarding BDNF serum levels in patients with obsessive-compulsive disorder (OCD). The aims of the present study were: 1) to assess the serum BDNF content in a sample of drug-naïve patients with OCD and 2) to assess whether putative alterations in peripheral BDNF may be associated to OCD severity and clinical characteristics. Methods: Twenty-four drug-naïve patients with a principal diagnosis of OCD were recruited. In parallel, a control group of 24 unrelated volunteers matched for gender and age was enrolled. Serum BDNF levels were measured by ELISA method. Results: The results showed that BDNF levels were decreased in OCD patients when compared to controls (36.90 ± 6.42 ng/ml versus 41.59 ± 7.82 ng/ml; p = 0.043). No correlations were evidenced between serum BDNF content and the severity of OCD symptoms measured as Y-BOCS scores or other clinical variables. Limitations: The choice of drug-naïve patients with obsessive-compulsive disorder had limited the size of the sample and excluded the recruitment of patients with a severe symptomatology. Conclusions: Our findings reveal for the first time in OCD patients a decrease in serum BDNF levels. These data corroborate the hypothesis of a dysfunction in the neurotrophin expression in the OCD pathogenetic mechanism and provide the rationale for further investigations directed to the identification of novel biomarkers and new therapeutic strategies for antiobsessional treatments.

KW - BDNF

KW - Brain-derived neurotrophic factor

KW - Drug-naïve

KW - Obsessive-compulsive disorder

KW - OCD

KW - Serum

UR - http://www.scopus.com/inward/record.url?scp=77649182475&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77649182475&partnerID=8YFLogxK

U2 - 10.1016/j.jad.2009.07.009

DO - 10.1016/j.jad.2009.07.009

M3 - Article

C2 - 19664825

AN - SCOPUS:77649182475

VL - 122

SP - 174

EP - 178

JO - Journal of Affective Disorders

JF - Journal of Affective Disorders

SN - 0165-0327

IS - 1-2

ER -